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Abstract 
 
There is a clinical need for reliable biomarkers for lung cancer that permit early diagnosis of the 
disease and provide prediction of histological phenotype. A prospective study design was used 
with a study population of patients with suspected lung cancer. Blood samples were collected 
from 17 patients with histologically confirmed squamous cell lung carcinoma, 17 individuals with 
adenocarcinoma, and 17 control individuals who did not subsequently have a diagnosis of lung 
cancer or any other cancer. Blood plasma samples were analysed for their lipid profiles using 
liquid chromatography coupled with high resolution mass spectrometry. Data were analysed 
using multivariate statistical methods. There was good separation between histological subtypes 
and control groups and also between individuals with a subsequent diagnosis of adenocarcinoma 
and squamous cell carcinoma (sensitivity 80%, specificity 83%, Q2=0.70). Alterations in the levels 
of different classes of lipids including triglycerides (TGs), phosphatidylinositols (PIs), 
phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), free fatty acids, 
lysophospholipids and sphingolipids were observed in squamous carcinoma and 
adenocarcinoma lung cancer patients when compared with control patients. In conclusion, this 
study has identified candidate lipid biomarkers of non-small cell lung cancer patients which may 
be helpful to indicate the tumour subtype and to differentiate them from patients who do not have 
lung cancer. Measuring these biomarkers has the potential to improve diagnosis in patients with 
suspected lung cancer and risk stratification in screening. 
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Introduction 
Worldwide, more than 1.8 million people were newly diagnosed with lung cancer in 2012, and it 
now represents the leading global cause of death from cancer, accounting for 19.4 % of all 
cancer deaths in recent years (GLOBOCAN 2012). 75% of patients with lung cancer present 
with advanced, incurable disease (Oak et al. 2012), which is associated with five year survival 
rates of approximately 9% (De Angelis et al. 2014). However, survival rates are significantly 
better in those individuals who present earlier, with five year survival rates of 60-75% (Scott et 
al. 2007). Lung cancers are generally divided into two main categories: small cell lung cancer 
and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 90% of all lung 
cancers. NSCLC is divided further into adenocarcinoma, squamous cell carcinoma (SCC), and 
large cell carcinoma histologies (Cheng et al. 2012). Lung cancer is often insidious, and it may 
produce no symptoms until the disease is well advanced. Approximately 7-10% of patients with 
lung cancer are asymptomatic, and their cancers are diagnosed incidentally after a chest 
radiograph performed for other reasons (Maghfoor I, 2014). While the management options for 
lung cancer have increased substantially in the past decade, rapid diagnosis remains a 
challenge and new diagnostic tests would have the potential to benefit a large number of 
patients. In addition, new diagnostic tests for lung cancer would (together with existing 
investigations) have potential as prognostic and responsiveness to treatment indicators. 
 
There is thus a pressing need for a new biofluid-based screening test that can identify high-risk 
individuals who can then be investigated using more invasive tissue biopsy methodology 
(Hassanein et al. 2012). The crucial role of lipids in cell, tissue and organ physiology is 
demonstrated by a large number of genetic studies and by many human diseases that involve 
the disruption of lipid metabolic enzymes and pathways (Wenk, 2005). A number of LC-MS 
methods have been applied to discover serum biomarkers of tumours, including those with high 
mortality, such as ovary, lung, liver, and pancreatic cancer. To date the large majority of these 
biomarkers have been identified as peptides or proteins. Proteomic analytical techniques 
(Yanagisawa et al. 2003, Hassanein et al. 2011) have been used in the study of lung cancer, 
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and this has yielded protein biomarkers that have been demonstrated to have high specificity in 
a study of 54 individuals diagnosed with NSCLC (Zeng et al. 2011). Serologic biomarkers of 
lung cancer have emerged recently: these include carcinoembryonic antigen, the cytokeratin 19 
fragment CYFRA21-1, cancer antigen CA-125 (Cedres et al. 2011), plasma kallikrein (Chee et 
al. 2008), progastrin-releasing peptide (ProGRP), and neuron-specific enolase (NSE) (Wojcik et 
al. 2008). However, there are relatively few studies of small molecule serological biomarkers of 
lung cancer. Lipids have a prominent biology in lungs as surfactants (Serrano et al., 2006) and 
prostanoids (Keith et al. 2006), and in phospholipid signalling-related cancer biology (e.g. PI3-
kinase ((Kong et al. 2008)).  
 
Most of the studies of the role of lipids in lung cancer involve the targeted analysis of specific 
lipids. There is evidence for the involvement of oxylipins (Poczobutt et al. 2006) and 
phospholipid species (Tyurina et al. 2011) in tumour development from animal models of lung 
cancer. This is supported by clinical studies showing altered profiles of various lipids in plasma 
of lung cancer patients, including lysophospholipids (Dong et al. 2010; Guo et al. 2012), free 
fatty acids (Liu et al. 2014), sphingomyelins, plasmalogens, phosphoglycerides and related 
lipids (Smith et al. 2008; De Castro et al. 2008; Ma et al. 2011).  Lipid profiling or lipidomics is 
an emerging field within metabolomics which focuses on monitoring changes in biofluid profiles 
of lipids and factors that interact with lipids. The chemical complexity of lipids, with many classes 
and sub-classes, makes lipid profiling of biofluids a challenging task (Yang et al. 2011). 
However, recent improvements in analytical approaches using ultra high performance liquid 
chromatography (UHPLC) and high resolution mass spectrometry (HRMS) make this field a 
promising new area for biomarker research (Yang et al. 2011, Gao et al. 2012, Haag et al. 2012). 
Here we apply UHPLC-HRMS lipidomics analysis to blood samples from patients with confirmed 
squamous cell or adenocarcinoma to test the hypotheses that blood small lipid molecules are 
biomarkers for lung cancer and can provide data to distinguish between squamous and 
adenocarcinoma histological sub-types of lung cancer.  
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Methods 
Study population 
The study population was recruited from individuals referred with suspected lung cancer to the 
lung cancer clinic at Nottingham University Hospitals. After providing consent, blood samples 
were collected in pre-chilled lithium heparin tubes and centrifuged within 30 min at 2000×g and 
4ºC for 10 min. Plasma was separated and immediately stored at -80°C until analysis. After the 
patients had received a diagnosis of squamous carcinoma or adenocarcinoma or confirmation 
that there was no evidence of lung cancer, the archived plasma samples were analysed for their 
lipid profiles. The study was approved by the Nottingham Research Ethics Committee 
(09/H0403/68). 
 
Reagents and materials 
A Milli-Q water purification system (Millipore, MA, USA) was used in the preparation of deionized 
water (18.2 mΩ). Acetonitrile, chloroform, ethyl acetate and hexane were HPLC grade purchased 
from Fischer scientific (Loughborough, UK). Methanol (LC-MS grade) and ammonium acetate 
were purchased from Sigma-Aldrich (Darmstadt, Germany). Isopropanol (LC-MS grade) and 
ethanol AR grade were obtained from Fischer Scientific (Loughborough, UK). 3,5 Di-tert-butyl-4-
hydroxytoluene (BHT) was purchased from Supelco (PA, USA).  
 
Sample preparation 
Lipids were extracted from plasma samples (50 µL) by adding 0.5 mL of ice-cold (-20°C) 
chloroform/methanol (1:2), the frozen plasma sample being allowed to thaw in the presence of 
the extraction solvent. After brief vortex-mixing (20 s), 0.5 mL of water was added to the tube 
contents and mixed again for 10 min, centrifuged at 1000 g for 10 min at 4°C. An aliquot of the 
lower lipophilic phase (100 µL) was removed and mixed with an equal volume of isopropanol 
prior to injection.  
 
Liquid chromatography-mass spectrometry (LC-MS) lipidomic analysis 
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LC-MS lipidomics analysis with high resolution mass spectrometry detection used an Accela high 
speed LC coupled to an Exactive MS (Thermo Fisher Scientific, USA). Data was acquired 
simultaneously in full scan ion mode (m/z 100-1200, resolution 25,000) in both positive and 
negative electrospray ionisation modes. The capillary temperature and heater temperature were 
maintained at 350º C and 300ºC respectively in both positive and negative modes. The maximum 
scan inject time and micro scans were 100 ms and 1 respectively.  LC-MS analysis was 
performed on an ACE C4, 300Å column (100×2.1 mm, 3 µm particle size; Phenomenex, 
Aberdeen, UK) maintained at a temperature of 40° C and a flow rate of 300 µL/min. The mobile 
phase consisted of (A) 5 mM ammonium acetate in water, (B) 5 mM ammonium acetate in 
methanol and (C) 5 mM ammonium acetate in acetonitrile. A binary gradient (30-100% B) from 
channels A, B was used for 0-16 min, 100% C for 16-18 min and 100%B from 19-20 min with a 
total run time of 20 min. The injection volume was 10 µL. All study samples and QC samples 
were analysed in a single continuous analytical run. 
 
Data Analysis and Metabolite Identification 
LC-MS raw data from the analysis of extracts of study and control samples were acquired using 
Xcalibur v2.1 software (Thermo Scientific, Hemel Hempstead UK). Each sample analysis 
produced a three dimensional data set consisting of m/z, retention time and ion signal intensity. 
The complete datasets from the adenocarcinoma, squamous patients, unknown histology 
patients and control groups were imported and processed by SIEVE v1.2 software (Thermo 
Scientific, Hemel Hempstead UK). Analytical method performance was validated by examining a 
representative set of 16 plasma lipids (details in Supplementary Information) in a series of QC 
samples prepared from a single separate source of control human plasma used in our laboratory 
(‘plasma QC’). for retention timeshifts, relative standard deviations (RSD%) of peak areas and 
mass accuracy. SIMCA-P 13.0.2 version (Umetrics AB, Umea, Sweden) was used to carry out 
multivariate analysis including principal component analysis (PCA) and orthogonal partial least 
square-discriminant analysis (OPLS-DA). OPLS-DA was used to investigate the differences in 
lipid profiles between the two lung cancer histological groups and the control group data sets. 
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Initial models based on the entire datasets (n=17 in each group) were internally cross-validated. 
Further prediction models were based on randomly selected training and test sets for each group 
with sensitivity and specificity calculations reported. Potential candidates for discriminant 
markers were selected using S-plots by setting the cutoff values for both covariance p(1) on x-
axis and the correlation value, p[corr] on y-axis. The two tails of S-plots represents the most 
contributing components to differentiate the two groups with more confidence and they are 
considered as potential candidates for discriminant lipid biomarkers. Candidates for discriminant 
biomarkers were also selected by variable importance in projection values (VIP) where VIP 
values greater than one were considered further as potential biomarkers. Tentative identification 
of key lipid biomarkers was achieved by using accurate mass determinations within a narrow m/z 
range (1 mDa in positive mode and 2 mDa in negative mode) to search appropriate metabolite 
databases including Lipid Maps (http://www.lipidmaps.org/) and the Human Metabolome 
database (http://www.hmdb.ca/).  
 
Results 
Demographics and clinical features of subjects 
Table 1 shows the baseline demographics of the subjects. The groups were similar in terms of 
age, sex, current or ex-smoking habit and co-morbidity. Although there were more subjects 
reporting weight loss in the squamous cancer and adenocarcinoma groups, a quarter of the 
controls also reported weight loss.  This reflected the nature of the controls, being patients 
rather than healthy volunteers.  
 
Validation of LC-MS lipidomic method performance 
The performance of the analytical LC-MS lipidomics method was evaluated using the plasma QC 
samples. All sample and plasma QC extracts were analysed in a single run where QC samples 
were interspaced with study samples. The plasma QC samples were closely clustered by PCA 
analysis and well separated from the study samples (Figure 1). In the QC datasets the %RSD 
values of peak areas of the representative plasma lipids were in the range of 5.6 to 10.2%, 
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retention time shifts were less than 0.1 min, the mass accuracy deviation ranged from 0.27 to 
0.80 mDa in positive ion mode and 0.17 to 1.21 mDa in negative ion mode (Full QC information 
is shown in Supplementary Table S6). These QC results validate the LC-MS lipidomics analytical 
performance during the analysis of the study samples. 
 
Plasma lipidomic analysis of non-small cell lung cancer patients and healthy volunteers 
Principal Component Analysis (PCA, unsupervised) was used to give an overview of the data 
sets but did not reveal any clear separation between the cancer and control groups (Figure 1). 
Supervised orthogonal partial least squares discriminate analysis (OPLS-DA) was used to 
analyse the data sets to generate models to differentiate between squamous carcinoma (n=17), 
adenocarcinoma (n=17) and control (n=17) subjects (Figure 2), and to identify discriminating lipid 
ions that contributed to the separation of cancer and control groups. OPLS-DA shows a 
reasonable separation between control samples and either squamous carcinoma or 
adenocarcinoma samples, but does not distinguish clearly between the squamous and 
adenocarcinoma patients when all three groups are included in a single analysis. Therefore, 
further analysis was undertaken to examine controls versus squamous carcinoma and controls 
versus adenocarcinoma datasets separately. 
 
Analysis of squamous carcinoma vs. control lipidomics data sets  
Using OPLS-DA analysis a clear separation was observed between squamous carcinoma 
samples and control samples (Figure 3). The S-plot (Supplementary Figure S8A) shows the 
contribution of the measured variables in both squamous carcinoma patients and control groups 
and it was used to guide the identification of potential lipid biomarkers in addition to VIP scores. 
To further validate the differences observed between the control and squamous carcinoma 
samples, the OPLS-DA model was validated using a training set containing 12 squamous 
carcinoma patients and 11 control patients and a test set containing  5 squamous carcinoma 
patients and 6 control patients. The model build using the training set was used to predict the 
status of test set subjects (Supplementary Figure S9). Despite the relatively small size of the 
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study, Table 5 shows that the calculated sensitivity and specificity values with 4 out of 5 
squamous carcinoma samples predicted correctly and 4 out of 6 control subject samples 
predicted correctly. The model was further validated by calculating area under receiver operating 
characteristic (ROC) curve (Eng 2007) (Figure 6A). 
Analysis of adenocarcinoma vs. control lipidomic data sets  
OPLS-DA analysis of the data sets generated from adenocarcinoma lung cancer patients (n=17) 
and healthy volunteers (n=17) gave separation between the two groups (Figure 4). The S-plot 
(Supplementary Figure S8B) shows the contribution of the measured variables in both 
adenocarcinoma patients and control groups and it was used to guide the identification of 
potential lipid biomarkers. As described previously, an OPLS-DA prediction model was built using 
subjects in the training set (adenocarcinoma patients (n=12) and control patients (n=11) to predict 
adenocarcinoma patients (adenocarcinoma patients (n=5) and control patients (n=6)). Using the 
prediction model 4 out of 5 adenocarcinoma samples were predicted correctly and 5 out of 6 
control subject samples were predicted correctly (Supplementary Figure S10) and sensitivity and 
specificity values are reported in Table 5. The model was validated by calculating area under 
receiver operating characteristic (ROC) curve (Figure 6B). 
Analysis of Adenocarcinoma Vs. Squamous datasets 
Finally, a supervised OPLS-DA model was generated which showed a clear separation between 
adenocarcinoma and squamous carcinoma patients (Figure 5). The potential biomarkers were 
identified using S-plot (Supplementary Figure S8C). A training set containing 12 adenocarcinoma 
patients and 11 squamous carcinoma patients and a test set containing 5 adenocarcinoma 
patients and 6 squamous carcinoma patients were used. The obtained R2X and Q2 values from 
training set were 0.61 and 0.70 respectively demonstrating an acceptable model. The model 
generated from training set was used to predict the classification of the remaining samples in test 
set. Finally, 4 out of 5 adenocarcinoma samples were predicted correctly and 5 out of 6 squamous 
carcinoma samples were predicted correctly (Supplementary Figure S11) and sensitivity and 
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specificity values of 80% and 83% respectively obtained (Table 5).  The model was further 
validated by calculating area under receiver operating characteristic (ROC) curve (Figure 6C). 
Plasma lipid biomarkers of squamous and adenocarcinoma 
Potential markers contributing strongly to the separation between the plasma lipid profiles of 
squamous carcinoma adenocarcinoma and control subjects were identified using S plots 
(Figure S7). The exact masses of these biomarkers were then used to interrogate 
metabolite/lipid databases  The biomarkers that contributed most to the squamous carcinoma 
signature were membrane lipids including triglycerides (TG), ceramides (CE), sphingomyelins 
(SM), phosphatidylcholines (PC), lysophosphatidylcholines (LysoPC) and 
phosphatidylethanolamines (PE) (Table 2) while the biomarkers that contributed to 
adenocarcinoma were triglycerides (TG), diglycerides (DG), phosphatidylserines (PS), fatty 
acids, plasmalogens, lysophosphatidylethanolamines (LysoPE) and phosphatidylethanolamines 
(PE) (Table 3). The biomarkers mostly contributed to the differentiation between 
adenocarcinoma and squamous carcinoma histological subtypes were phosphatidylinositol (PI), 
triglycerides (TG), ceramides (CE), sphingomyelins (SM), phosphatidylcholines (PC), 
phosphatidylethanolamines (PE) and plasmalogens (Table 4). Figure 7 shows elevated levels 
of  PS(36:1) observed in adenocarcinoma patients when compared to control and elevated 
levels of SM(d18:1/16:0) found in plasma of adenocarcinoma patients when compared with 
squamous carcinoma patients.  
 
Discussion 
We have used lipidomic analysis of blood plasma to classify those with and without lung cancer, 
and in those with lung cancer to distinguish between those having adenocarcinoma and 
squamous cell histological phenotypes. Our pilot data demonstrate the potential for this analytical 
methodology in the context of screening programmes for lung cancer and clinical management 
of patients with suspected lung cancer. In our small-scale study the obtained sensitivity and 
specificity values for the identification of adenocarcinoma were 80.0%, and 83.3% respectively 
and 80.0% and 66.7% for squamous carcinoma. These values are comparable with previous 
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protein-based biomarker studies for lung cancer which achieved sensitivity and specificity of 
86.9% and 80% respectively (Yang et al. 2005) and 87.3% and 81.9% (Sreseli et al. 2010) and 
>70% (Liu et al. 2014).  
 
The major strengths of our study are that the samples and controls were taken prospectively from 
patients attending the same cancer clinic with similar population demographics and that the 
analysis was performed by an investigator who was blinded to the cancer status.  The use of 
patients with suspected lung cancer who provided prospective blood samples prior to learning if 
they had lung cancer or not is also important, as the psychological stress experienced by both 
those with and those without cancer will be similar, and it is possible that this could manifest itself 
in the lipidomic signature if we used a ‘healthy’ population as our control group. The plasma 
samples were rigorously collected using a standardised protocol and the samples analyses were 
conducted with no awareness of the cancer status of the samples.  
 
Broadly, both squamous and adenocarcinomas were characterised by an increase in plasma di- 
and tri-glycerides and a decrease in phospholipids and lysophospholipids, although there were 
some exceptions to this (Tables 2&3). Cancer cells contain as high as 6.8% triglyceride fraction 
of total plasma membrane lipids (May et al. 1986). Changes in triglyceride levels in plasma have 
been associated with cancers (Ma et al. 2011, Fiorenza et al. 2000, Ulmer et al. 2009). Previous 
studies have noted a decrease in plasma phospholipids and lysophospholipids in advanced 
cancer, attributed to a loss of essential fatty acids in the periphery (Murphy et al. 2012, 2010, 
2007). Hence our observations are consistent with previous studies. The variations in the levels 
of phospholipid fatty acids between stages of disease may be based on many factors such as 
greater demand for phospholipid in the context of lung cancer because of higher levels of cell 
replication and modified phospholipid metabolism (Murphy et al. 2012). The involvement of 
lysophosphatidylcholine, a precursor of lysophosphatidic acid has been observed in the 
progression of ovarian and other cancers and abnormal levels of lysophospholipids in plasma 
may be indicators of the presence of cancer (Murphy et al. 2007).  
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The lipid biomarkers which contributed most to differentiate between adenocarcinoma and 
squamous carcinoma were phospholipids, triglycerides and sphingomyelins (Table 4). 
Phospholipids such as phosphatidylinositols are precursors for secondary messengers and 
involve in controlling of various cellular mechanisms like cell growth, motility and proliferation 
through definitive interactions of proteins which bind to their phosphorylated head groups. These 
play an important role in cancer biology. The 3-phosphorylated phosphoinositides are produced 
by phosphatidylinositol-3- kinases (PI3Ks) which are most common drug targets in cancer 
treatment. The mutation of PI3K enzyme in some cancers leads to increased levels of 3-
phosphorylated phosphoinositides which initiate growth factor stimulation and activation of 
protein kinase B and phosphoinositides dependent kinases (Fernandis et al. 2009, Wakelam et 
al. 2007). Plasmalogens contributed as suitable biomarkers in differentiating adenocarcinoma 
patients and healthy controls and also involved in differentiation of squamous and 
adenocarcinoma patients. Phospholipids that contain a vinyl ether-linkage are commonly known 
as plasmalogens. They involve in controlling of membrane fluidity and acts as mediators of 
membrane dynamics. They are also control the damage of nervous tissue associated with the 
accumulation of very long chain fatty acids. They are also have antioxidant capability and 
impaired and/or reduced levels of plasmalogens lead to human pathological disorders such as 
Alzheimer’s disease and metastatic cancer (Brites et al. 2004, Smith et al. 2008). 
The limitations of our data include the small size of the study population that is inevitable for a 
pilot study of a new technique. This may result in type II statistical error as we were unable to 
identify all small lipid molecules that contribute to the lipidomic signatures associated with non-
small cell lung cancers. We were also unable to adjust for other demographic and lifestyle 
exposures that may modify the lipidomic signatures associated with non-small cell lung cancer. 
However, the fact that we were able to see differences despite these limitations suggests that 
these observations need further study initially to clarify if they are consistent and replicatable. It 
is also recognised that the distinction between adenocarcinoma and squamous subtype based 
on small biopsies and histology can be a simplification of what is found when the whole tumour 
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is examined. A small proportion of whole tumours may contain both subtypes. This might explain 
some overlap between the two groups.   
 
The field of screening for non-small cell lung cancer is a challenging one to work in as definitive 
studies require high-risk populations of thousands of individuals to permit the detection of a 
clinically worthwhile difference in survival. Hence, the use of lipidomic methodology to permit the 
early assessment of individuals with suspected lung cancer is probably the field where these 
observations have the greatest potential to improve clinical care. In addition, we did not include 
individuals with small-cell lung cancer as this has a lower incidence and hence we would not 
have had sufficient power to permit identification of differences from those with either non-small 
cell lung cancer or no cancer, but clearly in larger studies this is an important group clinically. 
Although the effect of lung cancer on the plasma lipid signature may be responsible for our 
observed changes in the plasma lipid profiles, there may be other factors that we have not 
specifically considered such as diet, medication and nutrition which may also influence the lipid 
profile.  
 
In conclusion, this small pilot study of the use of lipidomics has demonstrated that a lipidomics 
approach can identify individuals with non-small cell lung cancer from those who do not have 
lung cancer, and also has the potential to distinguish individuals with adenocarcinoma lung 
cancer from those with squamous cell lung cancer, prior to diagnosis. The next step is for larger 
studies that also include patients with small cell lung cancer to assess the potential of lipidomic 
signatures in the management of patients in the lung cancer clinic. 
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Figure 1: Principal component analysis (PCA) scores plot obtained from all lung cancer study 
samples (squamous carcinoma – triangles  (n=17), adenocarcinoma - inverted open triangles 
 (n=17) and healthy individuals – squares  (n=17)), and QCs –circles ) (n=12) samples 
(R2X=0.710, Q2=0.390, A=11, N=63).  
Figure 2:  Orthogonal partial least squares discriminant analysis (OPLS-DA) scores plot obtained 
from squamous carcinoma samples (triangles ), adenocarcinoma samples (open inverted 
triangles ) and control samples (squares ) (R2X=0.260, R2Y=0.879, Q2=0.452, A=1+2+0, 
N=51).   
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Figure 3:   OPLS-DA scores plot obtained from squamous carcinoma (triangles ) and 
control (squares ) samples. (R2X=0.262, R2Y=0.668, Q2=0.181, A=1+1+0, N=34)  
 
Figure 4: OPLS-DA scores plot obtained from adenocarcinoma (open inverted triangles 
) and control (squares ) samples. (R2X=0.302, R2Y= 0.642, Q2=0.368, A=1+1+0, 
N=34) 
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Figure 5: OPLS-DA scores plot obtained from adenocarcinoma (inverted open triangles 
) and squamous carcinoma (triangles ) samples. (R2X=0.439, R2Y= 0.874, 
Q2=0.635, A=1+2+0, N=34) 
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Table 1:  Baseline demographics of the participants recruited to the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N= number of participants  
% = Percentage of participants   
  
 Squamous cell 
carcinoma  
N= 17 
Adenocarcinoma 
N= 17 
Controls 
N=17 
 
Age in years, median 
(range) 
69 
(41 to 89) 
75 
(57 to 88) 
70 
(54 to 90) 
 
Gender, males N (%) 13  
(76) 
10  
(60) 
9  
(53) 
 
Smoker or ex-smoker  N 
(%) 
16 (94) 17 (100) 13 (76) 
 
Weight loss  N (%) 
 
11 (65) 6 (35) 4 (24) 
Co-morbidity N (%)* 
 
17 (100) 16 (94) 13 (76) 
Number of medications, 
median (range) 
4 (0-11) 4 (0-8) 2 (0-9) 
Diagnosis of COPD N (%) 2 (12) 2 (12) 4 (24) 
Diagnosis of hypertension 
N (%) 
3 (18) 4 (24) 2 (12) 
Diagnosis of diabetes 
mellitus N (%) 
1 (6) 1 (6) 2 (12) 
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Table 2: Biomarkers showing differences between squamous carcinoma patients and 
control subjects 
 
Biomarker    
MW (Da) 
Formula 
Difference 
(mDa) 
Lipid tentative 
identification 
Adduct 
Squamous 
carcinoma 
     ↓↑ 
463.3491 C22H42NO7P 0.67 Unknown M+H        ↑ 
878.7333 C57H98O6 0.25 TG(54:6) M+H        ↑ 
880.749 C57H100O6 0.24 TG(54:5) M+H        ↑ 
864.7206 C56H96O6 0.38 Unknown M+NH4        ↑ 
882.7634 C57H102O6 0.37 TG(54:4) M+H        ↑ 
326.0003 C17H10O7 0.53 Unknown M+H        ↑ 
884.7832 C57H104O6 0.33 TG(54:3) M+Na        ↑ 
327.9965 C10H7O8N3P 0.28 Unknown M+H        ↑ 
882.7523 ------ ------ Unknown M+H        ↑ 
464.3536 ------ ------ Unknown M+H        ↑ 
919.7595 C59H98O6 0.29 TG(58:8) M+H        ↑ 
757.5612 C42H80NO8P 0.43 PC(34:2) M+H        ↓ 
785.5902 C44H84NO8P 0.27 PC(36:2) M+H        ↓ 
523.3632 C26H54NO7P 0.07 LysoPC(18:0) M+H        ↓ 
648.5845 C45H76O2 0.23 CE(18:2) M+NH4        ↓  
814.6927 C47H95N2O6P 0.01 SM(d18:0/24:1) M+H        ↓ 
769.5621 C43H80NO8P 0.40 PE(38:3) M+NH4        ↓ 
495.3312 C24H50NO7P 0.08 LysoPC(16:0) M+H        ↓ 
 
 
Mass Difference (mDa) is the difference in exact mass between the measured value 
and the theoretical value 
↑↓ - increase or decrease of biomarker compared with control group 
PC phosphatidylcholine; DG diacylglycerol; TG triglyceride; SM sphingomyelin; PE 
phosphatidylethanolamine; LysoPC  lysophosphatidylcholine; CE ceramide; 
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Table 3: Biomarkers showing differences between adenocarcinoma patients and 
control subjects 
 
Biomarker    
MW (Da) 
Formula 
Difference 
(mDa) 
Lipid tentative 
identification 
Adduct 
Adenocarcinoma 
             ↓↑ 
758.5742 ------ ------ Unknown M+H ↑ 
784.5892 ------ ------ Unknown M+H ↑ 
789.5519 C42H80NO10P 0.48 PS(36:1) M+NH4 ↑ 
860.6893 C56H92O6 0.49 Unknown M+NH4 ↑ 
791.5468 C45H78NO8P 0.03 PE(40:6) M-H ↑ 
310.2878 C20H38O2 0.10 Eicosenoic acid M-H ↑ 
926.7442 ------ ------ Unknown M+H ↑ 
338.3188 C22H42O2 0.205 Erucic acid M-H ↑ 
976.7519 C65H100O6 0.18 TG(62:13) M+NH4 ↑ 
664.5066 C43H68O5 0.34 DG(40:8) M+NH4 ↑ 
960.8145 C63H108O6 0.14 TG(60:7) M+NH4 ↑ 
280.2408 C18H32O2 0.046 Linoelaidic acid M-H ↑ 
793.5621 C45H80NO8P 0.50 PE(40:5) M+NH4 ↓ 
751.5528 C43H78NO7P 0.686 Plasmalogen(38:4) M-H ↓ 
727.5528 C41H78NO7P 0.686 Plasmalogen(36:2) M-H ↓ 
692.5379 C45H72O5 0.38 DG(42:8) M+Hac-H ↓ 
668.5379 C43H72O5 0.28 DG(40:6) M+Hac-H ↓ 
765.5308 C43H76NO8P 0.46 PE(38:5) M+NH4 ↓ 
749.5368 C43H76NO7P 0.34 Plasmalogen(38:5) M-H ↓ 
729.5688 C41H80NO7P 0.11 Plasmalogen(36:1) M-H ↓ 
481.3178 C23H48NO7P 0.04 LysoPE(18:0/0:0) M-H ↓ 
 
Mass Difference (mDa) is the difference in exact mass between the measured value 
and the theoretical value 
↑↓ - increase or decrease of biomarker compared with control group 
PS phosphatidylserine; DG diacylglycerol; TG triglyceride; PE 
phosphatidylethanolamine; LysoPE lysophosphatidylethanolamine 
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Table 4: Biomarkers showing differences between adenocarcinoma and squamous 
patients  
 
Biomarker    
MW (Da) 
Formula 
Difference 
(mDa) 
Lipid tentative 
identification 
Adduct 
Adenocarcinoma 
Squamous 
carcinoma 
↓↑ ↓↑ 
603.5292 ------ ------ Unknown M+H ↑ ↓ 
862.5571 C45H83O13P 0.36 PI(36:2) M+H ↑ ↓ 
757.5622 C42H80NO8P 1.45 PC(34:2) M+Hac-H ↑ ↓ 
743.5829 C42H82NO7P 0.15 Plasmalogen(34:1) M-H20-H ↑ ↓ 
219.3668 ------ ------ Unknown M-H ↑ ↓ 
765.5978 ------ ------ Unknown M-H ↑ ↓ 
792.6267 C51H84O6 0.49 TG(48:7) M-H ↑ ↓ 
731.6067 C41H84N2O6P 0.32 SM(d18:1/18:0) M+Hac-H ↑ ↓ 
874.705 C57H94O6 0.024 TG(54:8) M-H ↑ ↓ 
717.5672 C40H80NO7P 0.015 Plasmalogen(32:0) M-H20-H ↑ ↓ 
771.6142 C44H86NO7P 1.22 Plasmalogen(36:1) M-H20-H ↑ ↓ 
703.5754 C39H80N2O6P 0.29 SM(d18:1/16:0) M-H20-H ↓ ↑ 
587.3678 ------ ------ Unknown M-H ↓ ↑ 
719.5465 C39H78NO8P 0.27 PE(34:0) M+H ↓ ↑ 
819.5718 ------ ------ Unknown M-H ↓ ↑ 
444.3603 C29H48O3 0.21 
4alpha-Carboxy-
4beta-methyl-
5alpha-cholesta-8-
en-3beta-ol 
M+Hac-H ↓ ↑ 
666.5618 ------ ------ Unknown M-H ↓ ↑ 
809.6745 C48H91NO8 0.078 
Glucosylceramide 
(d18:1/24:1) 
M+NH4 ↓ ↑ 
 
Mass Difference (mDa) is the difference in exact mass between the measured value 
and the theoretical value 
PI phosphatidylinositol; PC phosphatidylcholine; TG triglyceride; SM sphingomyelin; PE 
phosphatidylethanolamine;  
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Table 5: Prediction of lung cancer patients based on OPLS-DA multivariate models 
OPLS-DA model 
Training set Test set 
Sensitivity 
(%) 
Specificity 
(%) 
Squamous 
carcinoma 
Adeno- 
carcinoma 
Healthy 
volunteers 
Squamous 
carcinoma 
Adeno-
carcinoma 
Healthy 
volunteers 
Squamous carcinoma 
Vs. control 
12  -----  11 5  -----  6 80  66.7  
Adenocarcinoma Vs. 
Control 
 ----- 12 11  -----  5 6 80  83.3  
Adenocarcinoma Vs. 
Squamous carcinoma 
12 11  -----  5 6   ----- 80  83.3  
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Figure 6: ROC curve is defined as true positive fraction versus false positive fraction. 
To affirm the validity of prediction OPLS-DA models of (A) squamous carcinoma vs 
control; (B) adenocarcinoma vs control; and (C) adenocarcinoma vs squamous 
carcinoma. Area under receiver operating characteristic (ROC) curves were calculated 
for each comparison. The area under the curve values were 0.86, 0.94 and 0.96 for 
squamous carcinoma vs control, adenocarcinoma vs control and adenocarcinoma vs 
squamous carcinoma (an ideal model would have an AUC of 1) which clearly states that 
the prediction models were robust. 
A) 
B) 
C) 
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Figure 7: Box and whisker plots demonstrated altered levels of PS(36:1), plasmalogen 
(38:5) (adenocarcinoma vs control) and SM(d18:1/16:0) (adenocarcinoma vs 
squamous carcinoma) which were significant when compared groupings between 
control (n=17), squamous carcinoma (n=17) and adenocarcinoma (n=17). Statistical 
analysis performed using unpaired  t-test, ***p<0.050 with Bonferroni correction.. 
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Figure S8: (A) S plot obtained from squamous carcinoma (n=17) and control (n=17) 
samples. (R2X=0.262, R2Y=0.668, Q2=0.181, A=1+1+0, N=34) Figure S9: (B) S plot 
obtained from adenocarcinoma (n=17) and control (n=17) samples. (R2X=0.302, R2Y= 
0.642, Q2=0.368, A=1+1+0, N=34); (C) S plot obtained from adenocarcinoma (n=17) 
and squamous carcinoma (n=17) samples. (R2X=0.670, R2Y= 0.419, Q2=0.302, 
A=1+1+0, N=34) 
 
 
 
 
 
Increasing 
confidence 
in squamous 
carcinoma 
Increasing 
confidence in 
adenocarcinoma 
Strong contribution 
in adenocarcinoma 
Strong contribution in 
squamous carcinoma 
33 
 
 
 
Figure S9: A) OPLS-DA scores plot (training set) obtained from squamous 
carcinoma (triangles ) and control (squares ) samples. (R2X=0.342, 
R2Y=0.705, Q2=0.293, A=1+1+0, N=23)  B) OPLS-DA prediction of 11 additional 
subjects 5 squamous carcinoma patients (open diamonds ) and 6 control 
samples (five point stars ). 
A) 
B) 
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Figure S10: A) OPLS-DA scores plot (training set) obtained from adenocarcinoma (open 
inverted triangles ) and Control (squares ) samples. (R2X=0.383, R2Y= 0.743, 
Q2=0.519, A=1+1+0, N=23) B) OPLS-DA prediction of 11 additional subjects 5 
adenocarcinoma (open diamond's ) and 6 control samples (five point stars ).  
 
A) 
B) 
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Figure S11: A) OPLS-DA scores plot (training set) obtained from randomly selected 33% 
adenocarcinoma (open inverted triangles ) and squamous carcinoma (    triangles ) 
patients. (R2X=0.612, R2Y= 0.995, Q2=0.699, A=1+4+0, N=23) B) OPLS-DA prediction 
of 11 additional subjects 5 adenocarcinoma (open five point stars ) and 6 squamous 
carcinoma samples (five point stars ). 
A) 
B) 
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Table S6: Reproducible peak areas and retention times of different lipids observed in 
plasma QC samples which were analysed during the lung cancer biomarker study 
Lipids %RSD peak area %RSD retention time Mass deviation mDa 
LysoPC(20:4) 8.95 0.47 0.43 
α or γ Linolenic acid 9.61 0.30 0.85 
Docohexaenoic acid 7.25 0.27 1.02 
LysoPC(15:0) 10.23 0.32 0.38 
LysoPC(16:0) 6.67 0.71 0.27 
Arachidonic acid 7.59 0.12 0.63 
LysoPC(18:1) 9.55 0.76 0.48 
Palmitoleic acid 6.32 0.20 0.96 
Linoleic acid 5.58 0.26 0.28 
LysoPC(18:0) 9.23 0.21 0.63 
LysoPE(22:6) 8.33 0.62 0.80 
Oleic acid 6.62 0.17 0.36 
13,14 Dihydro PGF1α 8.82 0.23 0.57 
Stearic acid 6.63 0.13 0.17 
Eicosanoic acid 6.66 0.29 0.95 
Ceramide (d18:1/16:0) 7.17 0.22 0.66 
Heptadecanoic acid 8.67 0.19 0.83 
Palmitic acid 6.82 0.31 0.99 
Palmitoyl glycerol 7.89 0.16 1.21 
HETEs 10.12 0.43 1.16 
DHETs 8.13 0.29 1.05 
 
LysoPC lysophosphatidylcholine; LysoPE  lysophosphatidylethanolamine; PGF1α 
prostaglandin F1α; PGF2α prostaglandin F2α; HETE hydroxyeicosatetraenoic acid; DHET 
dihydroxyeicosatrienoic acid; 
